Article Text

Unexpected outcome (positive or negative) including adverse drug reactions
Reversible hyponatraemia with venlafaxine in a young patient
  1. Qaiser Javed1,
  2. Faouzi Alam2,
  3. Sowmya Krishna2
  1. 1
    Wirral University Teaching Hospital, Psychiatry, Clatterbridge Hospital, Bebington, Wirral CH63 4JY, UK
  2. 2
    Clatterbridge Hospital, Psychiatry, Bebington, Wirral CH63 4JY, UK
  1. Qaiser Javed, drqaser{at}yahoo.co.uk

Summary

A 28-year-old woman with a depressive episode developed hyponatraemia (126 mmol/l), in the absence of hypovolaemia, oedema, or diuretic use, 2 weeks after starting treatment with the antidepressant venlafaxine. Full blood count, potassium, urea, creatinine, thyroid function test, liver function test, amylase, serum cortisol, and glucose were all normal. A repeat blood test 3 days later revealed a further reduction in the sodium concentration to 123 mmol/l. The patient did not have any signs or symptoms of physical disorder secondary to hyponatraemia on this occasion. Her serum sodium reached normal values 2 weeks after stopping treatment with venlafaxine. Hyponatraemia secondary to venlafaxine has been reported in the older population but not in young people. We therefore believe this is an important finding.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests: none.

  • Patient consent: Patient/guardian consent was obtained for publication